Characteristics | N* | Mean intensity | Positive N (%) | Negative N (%) | P |
---|---|---|---|---|---|
Type of samples | |||||
Normal control samples | 56 | 0.34 | 19 (33.9) | 37 (66.1) | |
Tumor from primary site | 289 | 0.72 | 187 (64.7) | 102 (35.3) | 0.0001 |
Tumor from metastasis | 103 | 0.72 | 76 (73.8) | 27 (26.2) | 0.5900 |
Age | |||||
< 1 year | 125 | 0.64 | 58 (46.4) | 67 (53.6) | 0.0002 |
> 1 year | 184 | 0.78 | 124 (67.4) | 60 (32.6) | |
Clinical stage | |||||
1 | 68 | 0.66 | 41 (60.3) | 27 (39.7) | 0.3700 |
4 | 103 | 0.75 | 69 (67.0) | 34 (33.0) | |
Specimen type | |||||
Mass screening | 55 | 0.31 | 24 (43.6) | 31 (56.4) | 0.0006 |
Standard | 234 | 0.8 | 160 (68.4) | 74 (31.6) | |
MYCN oncogene | |||||
Amplified | 34 | 0.52 | 21 (61.8) | 13 (38.2) | 0.1000 |
Not amplified | 214 | 0.69 | 100 (46.7) | 114 (53.3) |